Answers are grounded in this paper and cite their sources.
Immunoglobulin M (IgM) myelomas account for <0.5% of all myelomas (De Gramont et al, 1990) and are responsible for only a very small proportion of all IgM paraproteinaemias, estimated not to exceed 0.2% (Owen et al, 2000). In the largest published series, which included 10 patients, IgM myelomas were frequently associated with an immunophenotype negative for CD20, CD56 and CD117, the occurrence of a translocation t(11;14) and an aggressive clinical course with bad prognosis (Feyler et al, 2008), although the universality of these findings have been challenged (Willenbacher et al, 2008). In contrast, Waldenström Macroglobulinaemia (WM), which accounts for the vast majority of all IgM paraproteinaemias (Kyle & Garton, 1987), has recently been shown to be associated with the MYD88 L265P exon 5 mutation, which triggers interleukin-1 receptor–associated kinase (IRAK)-mediated nuclear factor (NF)-κB signalling in over 90% of cases (Treon et al, 2012). The analysis of the frequency of MYD88 mutations in WM-related lymphoid neoplasms (Varettoni et al, 2013; Xu et al, 2013) showed a positive mutational status in only 16/93 non-WM patients (Xu et al, 2013), and only 44/213 patients in (Varettoni et al, 2013), but included only 3 cases of IgM MM (Xu et al, 2013). To clarify whether MYD88 mutational analysis could help to make the clinically critical distinction between IgM MM and WM, we analysed 4 further cases of IgM MM with appropriate control samples and extended the analysis to exon 3 and exon 4 of the MYD88 gene. Patients with IgM Myeloma were identified by a search of the Austrian Myeloma Registry (AMR) database (www.myeloma.at), as well as an arrangement within the local pathology repository for sample availability. Clinical charts were reviewed for plausibility of the diagnosis (e.g. confirmation of lytic bone disease), together with analysis of the cytogenetic and immunophenotypic profile of the neoplasms for myeloma characteristics. Control samples with an established diagnosis of WM were taken from clinical routine diagnostics. DNA from 4 patients with IgM MM and 7 WM patients was extracted from formalin-fixed paraffin-embedded samples using the QIAGEN DNA easy kit (Qiagen, Hilden, Germany). For Sanger sequencing of the relevant exons, primers were used as described elsewhere (Pham-Ledard et al, 2012). Amplified polymerase chain reaction (PCR) products were isolated by the High Pure PCR-Product Purification kit (Roche, Vienna, Austria). For sequencing of the amplified fragments, the Big Dye Terminator v1.1 ready reaction cycle sequencing kit was used, as recommended by the manufacturer (Applied Biosystems, Vienna, Austria). An example is illustrated in Fig 1. Typical MYD88 L265P exon 5 mutations were confirmed in 6/7 patients with active WM and 0/4 patients with IgM MM. All samples were proven to be wildtype (wt) with respect to mutations in the exons 3 and 4 of the MYD88 gene (see Table 1 for details). We therefore confirmed the data published by Xu et al (2013) and add 4 more unmutated MYD88 IgM MMs to their 3 cases. To date, no overlap with MW has thus been described with respect to MYD88 mutational status. ‘Not to see the forest for the trees’ has always been the clinical challenge to diagnose the rare condition of IgM myeloma, which needs urgent treatment, in a deluge of IgM paraproteinaemias (Kyle & Garton, 1987; Owen et al, 2000) that are mostly due to WM, but also to other occasional IgM antibody producing B-cell proliferative entities [e.g., IgM monoclonal gammopathy of undetermined significance (MGUS), marginal-zone lymphomas, B-cell chronic lymphocytic leukaemia, mantle-cell lymphomas]. The conventional criteria, such as immunophenotypes and cytogenetic profiles, have shown conflicting results (Feyler et al, 2008; Willenbacher et al, 2008) and there is considerable overlap between all of these conditions. Furthermore, disease-driving IgH rearrangements are early events in both myeloma and lymphomagenesis (Morgan et al, 2012). Up to now, diagnosis rested mostly on clinical criteria (e.g. occurrence of lytic bone disease), impeding an early diagnosis of IgM myelomas. With the discovery of the MYD88 L265P mutation (Treon et al, 2012) as an almost universal genetic trait in WM, with only limited ‘spill over’ representation in other lymphomas, MGUS and myeloma (Varettoni et al, 2013; Xu et al, 2013), MYD88 mutational status has become a hallmark of WM and can be considered a putative ‘driver’ of this distinct entity, indicated by the higher transformation rate of MYD88-mutated IgM MGUS into frank WM, compared to wild-type cases (Varettoni et al, 2013). Our results might contradict a role for MYD88 exon 3 and exon 4 mutations in both WM and IgM MM, but a higher number of patients need to be investigated to confirm these findings. Furthermore, we added another 4 unmutated MYD88 IgM MM cases to the 3 cases previously described by Xu et al (2013). This distinct genetic trait could be exploited to discriminate these entities earlier in the disease course and with more precision to enable a more rationale therapy allocation to the benefit of our patients. This work was supported by the COMET Centre ONCOTYROL and funded by the Federal Ministry for Transport Innovation and Technology (BMVIT) and the Federal Ministry of Economics and Labour (BMWA), the Tiroler Zukunftsstiftung (TZS) as well as the Tyrolean society for the advancement of cancer research at Innsbruck, University (Tiroler Verein zur Förderung der Krebsforschung an der Universitätsklinik Innsbruck). Patient accrual was performed by the Austrian Myeloma Registry (www.myeloma.at) in accordance with the ethical review board (ERB) votes UN3252 266/4.2 and UN2616 243/4.2 of the ERB of the medical university of Innsbruck. W. W., C. M., Design of research; A. B., C. M., Experiments; W. W., E. W., A. B., C. M., Acquisition of materials, Analysis of data, Discussion of paper; W. W., Draft of paper. The authors do not report any conflict of interest with respect to the contents of this paper.
No takes yet. Share an insight, caveat, or question.
Willenbacher et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: